Call for papers: The Advances of CAR Immunotherapy within Oncology Clinics
Guest Editors: Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
BMC Cancer is currently accepting submissions to a thematic series entitled 'The Advances of CAR Immunotherapy within Oncology Clinics'.
Chimeric antigen receptor (CAR) T cells therapies, as a novel modality in cancer immunotherapy, provide a quantum leap in the treatment of cancer. In recognition of the new advances that the CAR approach represents in hematological malignancies, the Food and Drug Administration (FDA) recently approved two separate cell-based gene therapies, one from Novartis (Kamryah) the other from Gilead (Yescarta), for treatment of B cell leukemias. These concrete steps that advance the CAR therapy into the clinic provide the backdrop and motivation to assist the integration of the CAR immunotherapy into the standard treatment modalities of cancer. We envision that accelerated progress with clinical trials of CAR T cells, the proper dosing of engineered T cells along with optimized GMP-compliant production of patient-derived T lymphocytes, combination therapies using CAR T cells and additional chemo- and immune-therapies, and increased safety considerations with diminished side-effects will remain the focus of scientific investigations. As such, manuscripts dealing with any of these related topics fit within the scope of this new thematic series.
BMC Cancer, in collaboration with BMC Biotechnology, have agreed to jointly host the thematic series. To present the recent advances in the applications and safety of CAR immunotherapy, we invite you and/or members of your research team to submit manuscript(s) for this thematic series.
We are seeking submissions of original research articles (including systematic reviews and meta-analyses), but also commentary articles. This collection will also include invited reviews.
We would welcome direct submission of any original research you would like to be considered. Please submit directly to BMC Cancer or BMC Biotechnology stating in your cover letter that you are targeting the 'CAR Immunotherapy' collection